SCHEMBL15329899

SCHEMBL15329899

FC(F)(F)c1cc(P(c2cc(C(F)(F)F)cc(C(F)(F)F)c2)c2cc(C(F)(F)F)cc(C(F)(F)F)c2)cc(C(F)(F)F)c1.FC(F)(F)c1cc(P(c2cc(C(F)(F)F)cc(C(F)(F)F)c2)c2cc(C(F)(F)F)cc(C(F)(F)F)c2)cc(C(F)(F)F)c1.FC(F)(F)c1cc(P(c2cc(C(F)(F)F)cc(C(F)(F)F)c2)c2cc(C(F)(F)F)cc(C(F)(F)F)c2)cc(C(F)(F)F)c1.[Pd]

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.42
IDO1 P14902 2/20 0.38
GPR35 Q9HC97 2/20 0.34
ADRB1 P08588 1/20 0.34
TSHR P16473 3/20 0.33
ALDH1A1 P00352 2/20 0.33
MAPT P10636 1/20 0.33
RAPGEF4 Q8WZA2 1/20 0.33
ITGB3 P05106 1/20 0.33
ITGAV P06756 1/20 0.33
RXRA P19793 1/20 0.33
RXRB P28702 1/20 0.33
RXRG P48443 1/20 0.33
XPO1 O14980 1/20 0.31
CYP3A4 P08684 1/20 0.31
HPGD P15428 1/20 0.31
ALOX15 P16050 1/20 0.31
HIF1A Q16665 1/20 0.31
TXNRD1 Q16881 1/20 0.31
TXNRD3 Q86VQ6 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16823330 1.00 CES2 (0.42) CES2IDO1GPR35ADRB1TSHR
SCHEMBL10271930 1.00 CES2 (0.42) CES2IDO1GPR35ADRB1TSHR
SCHEMBL383565 0.97 CES2 (0.44) CES2IDO1GPR35ADRB1TSHR
SCHEMBL16861287 0.94 CES2 (0.42) CES2IDO1GPR35ADRB1TSHR
SCHEMBL26212657 0.85 RAPGEF4 (0.46) CES2IDO1MAPTRAPGEF4RXRA
SCHEMBL15338946 0.85 RAPGEF4 (0.46) CES2IDO1MAPTRAPGEF4RXRA
SCHEMBL16145497 0.84 CYP3A4 (0.52) IDO1TSHRALDH1A1MAPTRXRA
SCHEMBL6251039 0.79 TSHR (0.42) CES2IDO1TSHRALDH1A1MAPK1
SCHEMBL440959 0.78 CES2 (0.58) CES2IDO1GPR35ADRB1TSHR
SCHEMBL7798387 0.76 CES2 (0.46) CES2IDO1GPR35ADRB1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10793504-B2 Methods for cross coupling RECURIUM IP HOLDINGS, LLC (US) 2020-10-06 US claimed
US-20190202769-A1 METHODS FOR CROSS COUPLING RECURIUM IP HOLDINGS, LLC 2019-07-04 US claimed
EP-3504217-A1 METHODS FOR CROSS COUPLING Zeno Royalties & Milestones, LLC (US) 2019-07-03 EP claimed
WO-2018039232-A1 METHODS FOR CROSS COUPLING KALYRA PHARMACEUTICALS, INC. (US) 2018-03-01 WO claimed
US-9056314-B2 Palladium catalyst, method for its preparation and its use H4SEP KFT (HU) 2015-06-16 US claimed
US-20130281700-A1 PALLADIUM CATALYST, METHOD FOR ITS PREPARATION AND ITS USE CHINOIN GYOGYSZER-ES VEGYESZETI TER-MEKEK GYARA ZRT (HU) 2013-10-24 US claimed
CN-119823001-A Urea compounds antagonizing LPA1 receptor 大正制药株式会社 2025-04-15 CN disclosed
CN-114206832-B Urea compounds antagonizing LPA1 receptor 大正制药株式会社 2025-04-04 CN disclosed
CN-112638985-B Fluorine-containing aromatic polymer and method for producing same 大金工业株式会社 2024-03-15 CN disclosed
US-20230097871-A1 UREA COMPOUND FOR ANTAGONIZING LPA1 RECEPTOR TAISHO PHARMACEUTICAL CO., LTD. (JP) 2023-03-30 US disclosed
US-20230069963-A1 PYRAZOLO[1,5-A]PYRIMIDINE MACROCYCLIC COMPOUND TAISHO PHARMACEUTICAL CO., LTD. (JP) 2023-03-09 US disclosed
EP-4008405-A1 UREA COMPOUND FOR ANTAGONIZING LPA1 RECEPTOR Taisho Pharmaceutical Co., Ltd. (JP) 2022-06-08 EP disclosed
CN-114206832-A Urea compounds antagonizing LPA1 receptor 大正制药株式会社 2022-03-18 CN disclosed
EP-2886545-B1 New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2016-06-29 EP disclosed
WO-2016066241-A1 PROCESS FOR PREPARING THIADIAZOLO-ISOINDOLE-DIONE DERIVATIVES MERCK PATENT GMBH (DE) 2016-05-06 WO disclosed
EP-2886545-A1 New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2015-06-24 EP disclosed
US-9056314-B2 Palladium catalyst, method for its preparation and its use H4SEP KFT (HU) 2015-06-16 US disclosed
US-9056314-B2 Palladium catalyst, method for its preparation and its use H4SEP KFT (HU) 2015-06-16 US disclosed
US-20130281700-A1 PALLADIUM CATALYST, METHOD FOR ITS PREPARATION AND ITS USE CHINOIN GYOGYSZER-ES VEGYESZETI TER-MEKEK GYARA ZRT (HU) 2013-10-24 US disclosed
US-20130281700-A1 PALLADIUM CATALYST, METHOD FOR ITS PREPARATION AND ITS USE CHINOIN GYOGYSZER-ES VEGYESZETI TER-MEKEK GYARA ZRT (HU) 2013-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230097871-A1 UREA COMPOUND FOR ANTAGONIZING LPA1 RECEPTOR LPAR1, LPAR2, LPAR3 CES2 3066/4885IDO1 1574/4885GPR35 139/4885
US-20190202769-A1 METHODS FOR CROSS COUPLING F2, C5, C9 CES2 1228/4885IDO1 167/4885GPR35 4410/4885
US-20230069963-A1 PYRAZOLO[1,5-A]PYRIMIDINE MACROCYCLIC COMPOUND ZC3HAV1, ZC3HAV1L, IL5 CES2 4883/4885IDO1 2757/4885GPR35 1195/4885
US-20130281700-A1 PALLADIUM CATALYST, METHOD FOR ITS PREPARATION AND ITS USE PDS5A, DDT, PDS5B CES2 2917/4885IDO1 208/4885GPR35 1922/4885
US-10793504-B2 Methods for cross coupling F2, C5, C9 CES2 1228/4885IDO1 167/4885GPR35 4410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.